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ABSTRACT
Objectives To examine the reporting characteristics and
methodological details of randomised trials indexed in
PubMedin2000and2006andassesswhetherthequalityof
reportinghasimprovedafterpublicationoftheConsolidated
StandardsofReportingTrials(CONSORT)Statementin2001.
Design Comparison of two cross sectional investigations.
Study sample All primary reports of randomised trials
indexed in PubMed in December 2000 (n=519) and
December 2006 (n=616), including parallel group,
crossover,cluster,factorial,andsplitbodystudydesigns.
Main outcome measures The proportion of general and
methodological items reported, stratified by year and
study design. Risk ratios with 95% confidence intervals
were calculated to represent changes in reporting
between 2000 and 2006.
Results The majority of trials were two arm (379/519
(73%) in 2000 v 468/616 (76%) in 2006) parallel group
studies (383/519 (74%) v 477/616 (78%)) published in
specialty journals (482/519 (93%) v 555/616 (90%)). In
both 2000 and 2006, a median of 80 participants were
recruited per trial for parallel group trials. The proportion
of articles that reported drug trials decreased between
2000and2006(from393/519(76%)to356/616(58%)),
whereas the proportion of surgery trials increased (51/
519 (10%) v 128/616 (21%)). There was an increase
between 2000 and 2006 in the proportion of trial reports
that included details of the primary outcome (risk ratio
(RR) 1.18, 95% CI 1.04 to 1.33), sample size calculation
(RR 1.66, 95% CI 1.40 to 1.95), and the methods of
random sequence generation (RR 1.62, 95% CI 1.32 to
1.97) and allocation concealment (RR 1.40, 95% CI 1.11
to1.76).Therewasnodifferenceintheproportionoftrials
that provided specific details on who was blinded (RR
0.91, 95% CI 0.75 to 1.10).
Conclusions Reporting of several important aspects of
trial methods improved between 2000 and 2006;
however, the quality of reporting remains well below an
acceptable level. Without complete and transparent
reporting of how a trial was designed and conducted, it is
difficult for readers to assess its conduct and validity.
INTRODUCTION
The Consolidated Standards of Reporting Trials
(CONSORT) Statement, first published in 1996
1 and
revised in 2001,
2 provides recommendations for
authors regarding how to prepare reports of trial find-
ings. The aim of this 22 item checklist is to facilitate
complete and transparent reporting of trial findings
and aid their critical appraisal and interpretation. The
statementhasbeenendorsedbytheWorldAssociation
of Medical Editors, the International Committee of
Medical Journal Editors, the Council of Science Edi-
tors, and a significant number of journals worldwide.
3
More than twelve years have now passed since the
CONSORT Statement was first published and more
than eight years have passed since the statement was
last revised. A study of randomised trials published in
December 2000, before publication of the revised
CONSORT Statement in 2001, showed that many
items on the CONSORT checklist—such as details of
sample size calculations, primary outcomes, random
sequence generation, allocation concealment, and
handling of attrition—were inadequately described in
more than half of the publications assessed.
4
With further revisions of the CONSORT Statement
expected in 2010, it is timely to assess whether the
recommendations have led to improvements in the
quality of reports of randomised trials. In part one of
this study, we examine the extent to which reports of
randomised trials published in 2006 incorporate
recommendations from the CONSORT Statement.
In part two, we assess whether the quality of reports
of randomised trials has improved since a similar
assessment was conducted in 2000,
4 before the publi-
cation of the revised CONSORT Statement in 2001.
2
METHODS
Study sample
Weusedthe Cochranehighlysensitivesearchstrategy
(phase 1)
5 to identify primary reports of randomised
trials published in December 2006 and indexed in
PubMed by 22 March 2007. This search approach
was developed specifically to retrieve reports of con-
trolled trials from Medline by using PubMed.
5 One
reviewer screened the titles and abstracts of all
retrieved reports to exclude any obvious reports of
non-eligible trials. A copy of the full article was then
obtained for all non-excluded reports, and each full
articlewasassessedbythe samereviewertodetermine
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about the trial included as an appendix on the journal
website was also obtained, if available.
Wedefinedarandomisedtrialasaprospectivestudy
that assessed healthcare interventions in human parti-
cipants who were randomly allocated to study groups.
Studiesofcosteffectivenessortheaccuracyofdiagnos-
tic tests, and non-English language reports, were
excluded. Studies of parallel group, crossover, cluster,
factorial, and split body design were included. We
defined parallel group trials as studies where each par-
ticipant is randomised to one of the intervention arms.
Crossover trials were defined as trials where each par-
ticipant was exposed to each intervention in a random
sequence. Cluster trials were defined as trials in which
clustersofindividuals(forexample,clinicsandschools)
were randomly allocated to different study arms. Fac-
torial trials were defined as trials where participants
were randomly assigned to individual interventions or
a combination of interventions, and split body trials
weredefinedasthosewhereseparatebodypartswithin
each participant (for example, eyes) were randomised.
These definitions mirror those used in the original sur-
vey by Chan and Altman, which assessed 519 rando-
mised trials published in December 2000 and indexed
in PubMed by July 2002
4; however, their cohort also
included one trial report published in French.
Data extraction
Weextracteddetailsonanumberofgeneralandmeth-
odological items from each of the included articles.
General items were trial design,journaltype and med-
icalspecialty,typeofintervention,numberofdatacol-
lection sites, number of randomised groups, and
sample size. Methodological items were use of the
term “randomised” in the study title and specification
of the primary outcome, sample size calculation,
methodofrandomsequencegenerationandallocation
concealment, who was blinded, and how blinding was
achieved. Publication of a participant flow diagram,
details of loss to follow-up in each arm of the trial,
whether the trial stated that an intention to treat analy-
sis had been carried out, details of trial registration,
access to the trial protocol, and funding sources were
also analysed (box). We also assessed whether a trial
report was published in a journal that endorses the
CONSORT Statement on the basis of the journals’
instructions to authors (accessed June 2008).
Data extraction was carried out by three reviewers.
To ensure consistency in the data extraction process,
the three reviewers first completed data extraction for
ten articles and any disparities in the data obtained
were discussed. Differences were primarily owing to
differing interpretation of the data extraction form;
thus the form was modified and the exercise repeated
using a further ten articles until there was agreement.
Onceagreementontheinterpretationofthedataextra-
ctionformwasreached,thethreereviewerscarriedout
singledata extraction onall remainingarticles. Ifthere
was uncertainty regarding a particular article, the data
obtained were checked by a second member of the
review team and resolved by discussion.
Data analysis
Descriptive summary statistics were calculated for
each of the general and methodological items speci-
fied, and outcomes were stratified by study design.
The descriptive summary statistics were then used to
compare the quality of reporting for randomised trials
publishedinDecember2006withthequalityofreport-
ing in trials published in December 2000 (that is, in
thosetrialsassessedbytheoriginalsurveybyChanand
Altman
4). STATA (version 10) was used to calculate
risk ratios (RR) and absolute differences (AD) with
95% confidence intervals (CI) to quantify changes in
reporting between 2000 and 2006. Finally, for articles
published in 2006 we also compared the quality of
reporting for randomised trials published in journals
endorsing the CONSORT Statement with the quality
in journals that did not, recognising that there is a time
lag from when the journal article was published and
when the journalinstructionsto authorswere accessed
(June 2008).
RESULTS
Survey of randomised trials indexed in PubMed in
December 2006
The Cochrane highly sensitive search strategy identi-
fied 1735 citations that possibly linked to reports of
randomised trials. After screening the titles and
abstracts of all retrieved citations, we reviewed 879
full text articles and identified 616 primary reports of
Definitions used to assess reporting of methodological details in publications of
randomised trials
Primary outcome
E x p l i c i td e f i n i t i o no fp r i m a r yo rm a i no u t c o m e ( s )o ra no u t c o m eu s e di nt h es a m p l es i z e
calculation, or explicit description of a main outcome in the primary study objectives
Sample size
Sample size calculation stated to have been undertaken
Random sequence generation
Description of method for allocating participants to study groups, including computer
generated sequences, random number tables, and coin tosses
Allocation concealment
Description of method used to prevent individual participants from knowing or predicting
the allocation sequence in advance, including central randomisation or sealed envelopes
Blinding—who was blinded
Studyparticipants, outcomeassessors, careproviders,orinvestigatorswithnoknowledge
of the participants’ group allocation stated to be blinded; or the trial stated to be blinded,
single blind, double blind, or triple blind
Blinding—how blinding was achieved
Similarities between interventions or procedures described, or the trial stated to be
placebo controlled or unblinded
Attrition—loss to follow-up for each group
Losses to follow-up, with reasons, enumerated for all study groups
Intention to treat analysis
Randomised participants with available data stated as having been assessed in an
intention to treat analysis
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(fig 1). General and methodological characteristics
were stratified by trial design. In 2006, 316 different
journals published primary trial reports, with 25 jour-
nals publishing five or more randomised trials in the
singlemonthstudied.Themajorityoftrialreportswere
published in specialty journals (555/616 (90%)). The
highest number of reports appeared in the American
Journal of Cardiology (n=9), Anesthesia & Analgesia
(n=9), Journal of the American College of Cardiology
(n=9), New England Journal of Medicine (n=8), Journal of
Clinical Oncology (n=7), and Journal of Infectious Diseases
(n=7). All these journals are monthly apart from the
New England Journal of Medicine, which is weekly.
Table 1 provides information on general trial char-
acteristics. Over three quarters (477/616 (78%)) of
reports were of parallel group trials, 16% (100/616)
were crossover trials, and the remaining 6% (39/616)
were classified as “other”—more specifically, cluster
randomised (13/39), factorial (10/39), or split body
(16/39) trials. More than half (356/616 (58%)) of the
trials investigated drugs as the primary intervention
of interest, whereas 21% (128/616) assessed surgical
or procedural interventions, 18% (113/616) assessed
counselling or lifestyle interventions, and 3% (19/
616) assessed equipment or devices. Forty per cent
(248/616) of reports explicitly stated that the trial was
conducted at a single centre and 28% (172/616) stated
thatthetrialtookplaceatmultiplecentres;thenumber
of study centres was not explicitly defined in the
remaining reports (196/616 (32%)). The median num-
ber of participants recruited per trial was 62 (10th to
90th percentile 19 to 392). As expected, parallel
group trials were larger (median 80, 10th to 90th per-
centile28to418)thancrossovertrials(median20,10th
to 90th percentile 9 to 61).
Table 2 provides information on the reporting of
methodological items. A third (205/616 (33%)) of all
trial reports stated that the study was randomised in
thestudytitle,53%(324/616)definedtheprimaryout-
come, and 45% (279/616) stated that a sample size
PubMed citations identified (n=1735)
Full articles reviewed (n=879)
Citations excluded (n=856):
  Observational study (n=438)
  Review (n=154)
  Editorial or letter (n=80)
  Non-randomised study (n=61)
  Secondary publication (n=31)
  Diagnostic test study (n=25)
  Methodology study (n=21)
  Economic evaluation (n=14)
  Non-trial experiment (n=10)
  Study protocol (n=9)
  Qualitative study (n=6)
  Non-human study (n=3)
  Guidelines (n=2)
  Case report (n=2)
Total randomised trials assessed (n=616)
Full articles excluded (n=263):
  Secondary publication (n=100)
  Non-randomised study (n=46)
  Observational study (n=44)
  Non-trial experiment (n=33)
  Editorial or letter (n=10)
  Review (n=7)
  Interim analysis report (n=6)
  Diagnostic test study (n=4)
  Economic evaluation study (n=3)
  Study protocol (n=3)
  Case report (n=2)
  Methodology study (n=2)
  Non-human study (n=1)
  Qualitative study (n=1)
  Non-English language study (n=1)
Fig 1 | Identification of randomised trials from PubMed
citations indexed in December 2006
Table 1 |General characteristics of randomised trials indexed in PubMed in December 2006
All trials
(n=616)
Trial type
Parallel group
(n=477)
Crossover
(n=100)
Other*
(n=39)
Journal type
Specialty 555 (90%) 424 (89%) 99 (99%) 32 (82%)
General medical 61 (10%) 53 (11%) 1 (1%) 7 (18%)
Top five speciality areas
Cardiology
68 (11%)
Cardiology
57 (12%)
Physiology
30 (30%)
Dentistry
5( 1 3 % )
Psychiatry
57 (9%)
Psychiatry
48 (10%)
Respiratory medicine
8( 8 % )
Ophthalmology
5( 1 3 % )
Physiology
53 (9%)
Surgery
33 (7%)
Cardiology
7( 7 % )
Psychiatry
5( 1 3 % )
Paediatrics
38 (6%)
Paediatrics
32 (7%)
Pharmacology
6( 6 % )
Infectious disease
4( 1 1 % )
Surgery
38 (6%)
Neurology
31 (6%)
Dentistry
6( 6 % )
Cardiology
4( 1 0 % )
Journal stance on CONSORT Statement† †
CONSORT endorsing journal 274 (44%) 231 (48%) 30 (30%) 13 (33%)
Non-endorsing journal 342 (56%) 246 (52%) 70 (70%) 26 (67%)
Intervention
Drug 356 (58%) 278 (58%) 66 (66%) 12 (31%)
Surgery or procedure 128 (21%) 102 (21%) 16 (16%) 10 (26%)
Counselling or lifestyle
interventions
113 (18%) 87 (18%) 13 (13%) 13 (33%)
Equipment or devices 19 (3%) 10 (2%) 5 (5%) 4 (10%)
Study centres‡ ‡
Single 248 (40%) 184 (39%) 42 (42%) 22 (56%)
Multiple 172 (28%) 153 (32%) 9 (9%) 10 (26%)
Unclear 196 (32%) 140 (29%) 49 (49%) 7 (18%)
Number of study groups
Two 468 (76%) 374 (78%) 64 (64%) 30 (76%)
Three 97 (16%) 69 (15%) 27 (27%) 1 (3%)
Four 35 (5%) 21 (4%) 7 (7%) 7 (18%)
More than four 16 (3%) 13 (3%) 2 (2%) 1 (3%)
Sample size
Median per trial
(10th to 90th percentile)
62 (19 to 392) 80 (28 to 418) 20 (9 to 61) 86 (20 to 1571)
Median per treatment group
per trial (10th to 90th
percentile)
36(13to241)§ 34 (12 to 187) NA 376 (28 to 668)¶
*Includes cluster (n=13), factorial (n=10) and split body (n=16) trials.
†According to journal instructions to authors, assessed June 2008.
‡Explicitly stated as single centre or multicentre, otherwise defined as unclear.
§n=500 trials; excludes crossover and split body trials.
¶n=23 trials; excludes crossover and split body trials.
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generate the random sequence for allocating partici-
pants to study groups was reported in just over a third
(209/616(34%))oftrialreports,andaquarter(156/616
(25%))reportedthemethodusedtopreventtheperson
enrolling participants from knowing or predicting the
allocation sequence.
Fifty-nine per cent (362/616) of publications
reported details of any blinding. Of these, 44% (160/
362)providedspecificdetailsonwhowasblindedafter
assignment to interventions (for example, study parti-
cipants, outcome assessors, care providers), whereas
the remaining 56% (202/362) simply used the terms
“blinded,”“ single blind,” or “double blind” without
providing further details. In addition to reporting
who was blinded, 41% (254/616) of trial reports pro-
vided information on how blinding was achieved; of
these,45%(113/254)specificallydescribedanysimila-
rities between the interventions or procedures (for
example, identical in size, colour, and taste), whereas
the remaining 55% (141/254) simply used the term
“placebo” without providing further details.
A participant flow diagram depicting, for each
group,the numberofparticipantswhowererandomly
assigned, received the intended treatment, and were
analysed for the primary outcome was included in
28% (172/616) of study reports. Sixty-nine per cent
(422/616) of trials reported details of any loss of fol-
low-up for each study group; of these, 86% (362/422)
explicitly stated the reasons for attrition or reported
that there was no loss to follow-up. A third (188/616
(31%)) of trial reports stated that an intention to treat
analysis had been carried out. Very few trial reports
provided details of trial registration (58/616 (9%)) or
where the original trial protocol could be accessed (9/
616 (1%)). Details of funding sources were provided in
62% (380/616) of trial reports: 17% (107/616) of trials
were funded solely by industry, 11% (70/616) were
part funded by industry, and 32% (196/616) were not
industry funded. For all trials, the quality of reporting
was generally poorer for crossover trials than for para-
llel group trials (table 2).
Comparison of randomised trials indexed in PubMed in
2000 with those indexed in 2006
In both 2000 and 2006, the majority of trials involved
two study arms (379/519 (73%) in 2000 v 468/616
(76%) in 2006), had parallel group design (383/519
(74%) v 477/616 (78%)), with a median of 80 partici-
pantspertrial,andwerepublishedinspecialtyjournals
(482/519 (93%) v 555/616 (90%)). The proportion of
articles that reported drug trials decreased between
2000 and 2006 (from 393/519 (76%) to 356/616
(58%)), whereas the proportion of surgical trials
increased (from 51/519 (10%) to 128/616 (21%);
table 3).
Weidentifiedanincreasebetween2000and2006in
the proportion of trial reports that included details of
the primary outcome (RR 1.18, 95% CI 1.04 to 1.33;
AD 8%, 95% CI 2% to 14%), sample size calculation
(RR 1.66, 95% CI 1.40 to 1.95; AD 18%, 95% CI 12%
Table 2 |Reporting of methodological characteristics for randomised trials indexed in
PubMed in December 2006
All trials
(n=616)
Trial type
Parallel group
(n=477)
Crossover
(n=100)
Other*
(n=39)
“ “Randomised” ” stated in title
Stated 205 (33%) 180 (38%) 11 (11%) 14 (36%)
Not stated 411 (67%) 297 (62%) 89 (89%) 25 (64%)
Primary outcome
Defined 324 (53%) 276 (58%) 29 (29%) 19 (49%)
Not defined 292 (47%) 201 (42%) 71 (71%) 20 (51%)
Sample size calculation
Stated 279 (45%) 232 (49%) 33 (33%) 14 (36%)
Not stated 337 (56%) 245 (51%) 67 (67%) 25 (64%)
Method of random sequence generation
Reported 209 (34%) 176 (37%) 17 (17%) 16 (41%)
Computer 169 (81%) 146 (83%) 13 (76%) 10 (62%)
Random number table 23 (11%) 18 (10%) 2 (12%) 3 (19%)
Coin toss 4 (2%) 2 (1%) 1 (6%) 1 (6%)
Other† 13 (6%) 10 (6%) 1 (6%) 2 (13%)
Not reported 407 (66%) 301 (63%) 83 (83%) 23 (59%)
Method of allocation concealment
Reported 156 (25%) 141 (30%) 9 (9%) 6 (15%)
Envelopes 78 (50%) 73 (52%) 5 (56%) 0
Central 52 (33%) 47 (33%) 1 (11%) 4 (67%)
Pharmacy 22 (14%) 17 (12%) 3 (33%) 2 (33%)
Other‡ 4( 3 % ) 4( 3 % ) 0 0
Not reported 460 (75%) 336 (70%) 91 (91%) 33 (85%)
Blinding— —who was blinded
Any blinding 362 (59%) 277 (58%) 63 (63%) 22 (56%)
Details reported§ 160 (44%) 127 (46%) 18 (29%) 15 (68%)
Details not reported¶ 202 (56%) 150 (54%) 45 (71%) 7 (32%)
Unblinded# 149 (24%) 117 (25%) 26 (26%) 6 (15%)
Unclear 105 (17%) 83 (17%) 11 (11%) 11 (28%)
Blinding— —how blinding was achieved
Any blinding 254 (41%) 190 (40%) 50 (50%) 14 (36%)
Details reported** 113 (45%) 82 (43%) 22 (44%) 9 (64%)
Details not reported†† 141 (55%) 108 (57%) 28 (56%) 5 (36%)
Unblinded 147 (24%) 115 (24%) 26 (26%) 6 (15%)
Not reported 215 (35%) 172 (36%) 24 (24%) 19 (49%)
Participant flow diagram
Included 172 (28%) 155 (32%) 8 (8%) 9 (23%)
Not included 444 (72%) 322 (68%) 92 (92%) 30 (77%)
Attrition— —loss to follow-up for each group
Reported 422 (69%) 353 (74%) 45 (45%) 24 (62%)
Reason given‡‡ 362 (86%) 301 (85%) 41 (91%) 20 (83%)
Reason not given 60 (14%) 52 (15%) 4 (9%) 4 (17%)
Not reported 194 (31%) 124 (26%) 55 (55%) 15 (38%)
Attrition— —intention to treat analysis
Reported 188 (31%) 172 (36%) 6 (6%) 10 (26%)
Not reported 428 (69%) 305 (64%) 94 (94%) 29 (74%)
Trial registration
Reported 58 (9%) 53 (11%) 2 (2%) 3 (8%)
Not reported 558 (91%) 424 (89%) 98 (98%) 36 (92%)
Trial protocol
Reported 9 (1%) 6 (1%) 1 (1%) 2 (5%)
Not reported 607 (99%) 471 (99%) 99 (99%) 37 (95%)
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tion (RR 1.62, 95% CI 1.32 to 1.97; AD 13%, 95% CI
8%to18%)andallocationconcealment(RR1.40,95%
CI1.11to1.76;AD7%,95%CI2%to12%).Therewas
no difference in the proportion of trials that provided
specificdetailsonwhowasblindedafterassignmentto
interventions(RR 0.91, 95% CI0.75 to 1.10;AD −3%,
95% CI −8% to 3%; fig 2).
Comparison of journals endorsing the CONSORT Statement
with non-endorsing journals in 2006
We also compared the quality of reporting for rando-
mised trials indexed in journals that endorse the
CONSORT Statement with those in non-endorsing
journals for reports published in December 2006. We
identifiedasignificantlyhigherrateofreportingofkey
methodological items in CONSORT endorsing jour-
nals (fig 3). Interestingly, we observed that the propor-
tion of trial reports that provided specific details on
who was blinded after assignment to interventions
was higher in CONSORT endorsing journals (RR
1.53, 95% CI 1.17 to 1.99; AD 11%, 95% CI 4% to
18%), and a reverse scenario was true for those reports
that used the terms “blinded,”“ single blind,” or “dou-
ble blind” (RR 0.93; 95% CI 0.74 to 1.16; AD −3%,
95% CI −10% to 5%).
DISCUSSION
Principal findings of study
Ourstudyprovidesacomprehensiveassessmentofthe
design and reporting characteristics of a cohort of
PubMed indexed randomised trials published in
December 2006. It also provides an important com-
parison with a similar cohort of randomisedtrialspub-
lished in December 2000 that allows us to assess
whether the quality of reporting has improved over
time and, importantly, following the publication of
the revised CONSORT Statement in 2001 and before
itsrevision,whichwillbepublishedinearly2010(BMJ
in press). To our knowledge, our study and that by
Chan and Altman
4 are the only studies to provide a
comprehensive assessment of randomised trials that
covers a specified time period and is not restricted by
diseaseorjournaltype.Oursampleisrepresentativeof
trialsaccessibleinPubMed,whichistheprimaryinfor-
mation resource for clinicians and researchers.
Interestingly, we identified an increase in the num-
ber of reports of randomised trials in 2006 (n=616)
compared with 2000 (n=519). This difference may
reflect a true increase in the number of randomised
trials being published or could reflect an increase in
the number of journals being indexed on PubMed.
The majority of randomised trials reported in 2006
were two arm parallel group trials published in speci-
alty journals. The proportion of surgical trials in 2006
was higher than in 2000, whereas the proportion of
drugs trials decreased—a trend that has also been
reported elsewhere.
6 The worrying relatively small
sample sizes seen in our cohort may be an indication
that many trials are inadequately powered to detect
clinically important treatment benefits. It is important
to note that we only assessed reports of randomised
trials included in the PubMed database; therefore,
our findings might not be representative of all pub-
lished reports of trials.
Despiteclearevidenceofimprovedreportingofsev-
eral important aspects of trial methods, the quality of
reporting remains well below an acceptable level. In
2006, more than half of all trial reports definedthe pri-
mary outcome and provided information on blinding,
loss to follow-up, and funding source; however, just
under half of all reports detailed sample size calcula-
tions. Only a third or less provided information on
the method of random sequence generation or alloca-
tion concealment,or whetheran intentiontotreatana-
lysis had been carried out. Reporting of trial
registration details and access to the trial protocol was
rare. In our study, we did not assess whether an inten-
tion to treat analysis had been carried out correctly,
simplythatthe termwasstatedinthetrialreport;how-
ever, several studies have shown that this terminology
is often used inappropriately.
7-9
Comparison with other studies
Recent studies that have assessed the quality of report-
ing of randomisedtrials have generally been restricted
to trials in specific disease areas
10-15 or journal
types.
16-19 These studies show that considerable
All trials
(n=616)
Trial type
Parallel group
(n=477)
Crossover
(n=100)
Other*
(n=39)
Funding
Solely industry 107 (17%) 87 (18%) 16 (16%) 4 (10%)
Part industry 70 (11%) 48 (10%) 17 (17%) 5 (13%)
Non-industry 196 (32%) 147 (31%) 32 (32%) 17 (44%)
None 7 (1%) 7 (1%) 0 0
Unknown 236 (38%) 188 (39%) 35 (35%) 13 (33%)
*Includes cluster (n=13), factorial (n=10) and split body (n=16) trials.
†Includes alternation (n=2), army regiment number (n=1), telephone automation system (n=3), date of birth
(inadequate method of sequence generation; n=1), drawing lots (n=2), odd and even numbers [inadequate]
(n=1), shuffling cards (n=1), throwing dice (n=1), and web automation system (n=1).
‡Drugs dispensed by person independent to the trial (n=4).
§Article reports exactly who was blinded.
¶Report stated used the terms “blinded”, “single blind,” or “double blind,” or similar, without providing further
details on who was blinded.
#Trial stated as unblinded if explicitly stated as such or blinding clearly not possible.
**Article reports similarities between interventions or procedures.
††Trial stated as placebo controlled, without further details on how placebo control was achieved.
‡‡65 trial reports stated that there was no loss to follow-up (parallel n=43, crossover n=19, other n=3).
Primary outcome
Sample size calculation
Sequence generation
Allocation concealment
Blinding
1.18 (1.04 to 1.33)
1.66 (1.40 to 1.95)
1.62 (1.32 to 1.97)
1.40 (1.11 to 1.76)
0.91 (0.75 to 1.10)
324/616
279/616
209/616
156/616
160/616
0.5 1 2
Risk ratio (95% CI) Risk ratio (95% CI) Subgroup PubMed 2006
232/519
142/519
109/519
94/519
148/519
PubMed 2000
Events/Total
Favours
non-improvement
Favours
improvement
Fig 2 | Differences in reporting of methodological items between 2000 and 2006
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randomisedtrials,dependingonthearea assessed.For
example,asystematicreviewof122surgicaltrialspub-
lished in 2000 to 2003 found that no reports detailed
how the randomisation process was implemented,
only 24% reported details of the primary outcome,
and 26% reported details of blinding.
10 A separate
study of 67 ophthalmology trials published in 2005
found that details of sequence generation, allocation
concealment, participant flow diagrams, and sample
size calculations were reported for less than half of
the randomised trials assessed.
11
The situation may be worse in specific journals. For
example, a study of 7422 randomised trials published
in Chinese medical journals found that important
methodologicalcomponentssuchassamplesizecalcu-
lation, randomisation sequence, and allocation con-
cealment were documented in only a small minority
of trial reports (1%, 8%, and 0.3%, respectively).
16
More encouraging is a study of 253 randomised trials
published in five leading medical journals between
2002and2003,whichfoundthat80%oftrialsreported
sequencegeneration,48%reportedallocationconceal-
ment, 55% reported the blinding status of study parti-
cipants,83%reportedthesamplesizejustification,and
86%reportedaparticipantflowdiagram.
17Thesefind-
ingsmaywellbeanindicationofmorerigorousreport-
ing requirements in these journals.
There is considerable evidence to show that reports
of randomised trials that have inadequate or unclear
documentationofsequencegeneration,allocationcon-
cealment, and blinding lead to biased estimates of
intervention effects. A meta-epidemiological study of
146 meta-analyses found that in trials with subjective
outcomes, effect estimates were exaggerated when
allocation concealment was inadequate or unclear
(ratioofoddsratios0.69,95%CI0.59to0.82)orblind-
ing had not taken place (ratio of odds ratios 0.75, 95%
CI0.61to0.93).
20Anotherstudyfoundatrendtowards
larger estimates of treatment effects in publications
with inadequate or unclear reporting of random
sequence generation compared with those adequately
reporting methods (ratio of odds ratios 0.81, 95% CI
0.60 to 1.09).
21 Further details on the rationale and
importance of these items can be found in the CON-
SORT explanation and exploration paper.
22
Whenassessingthereportingofkeymethodological
items in CONSORT endorsing as opposed to
non-endorsing journals, we identified significantly
better reporting in CONSORT endorsing journals.
These results should be viewed with a certain amount
of caution, however, because there is a time lag in our
study between when journal articles were published
and when the journal instructions to authors were
accessed (June 2008). Nevertheless, these findings mir-
ror those of a recent systematic review, which con-
cluded that journal adoption of the CONSORT
Statementisassociatedwithimprovedreportingofran-
domised trials, although poor reporting is common.
23
Our study provides important baseline data against
which future revisions of the CONSORT Statement
can be measured.
Limitations of study
Our study has several limitations. We carried out only
single data extraction, and although we did our best to
minimise any inconsistency in the reviewers’ inter-
pretation, it is possible that errors may have accrued.
In addition, data extraction in 2000 and that in 2006
was carried out by different teams of reviewers; how-
ever, all reviewers conferred to try to ensure consis-
tency in the interpretation of data extraction items.
Table 3 |Reporting of general characteristics for randomised trials indexed in PubMed in
20004 compared with those indexed in 2006
PubMed 2000
(n=519)
PubMed 2006
(n=616)
Journal type
Specialty 482 (93%) 555 (90%)
General medical 37 (7%) 61 (10%)
Trial design
Parallel 383 (74%) 477 (78%)
Crossover 116 (22%) 100 (16%)
Other 20 (4%) 39 (6%)
Intervention
Drug 393 (76%) 356 (58%)
Surgery or procedure 51 (10%) 128 (21%)
Counselling or lifestyle intervention 55 (11%) 113 (18%)
Equipment or devices 20 (4%) 19 (3%)
Number of study groups
Two 379 (73%) 468 (76%)
Three to four 122 (24%) 132 (21%)
More than four 18 (3%) 16 (3%)
Sample size
Median per trial (10th to 90th percentile) 52 (12 to 310) 62 (19 to 392)
Median per treatment group per trial
(10th to 90th percentile)
32 (12 to 159)* 36 (13 to 241)†
*n=393 trials; excludes crossover, split body trials, and n of 1 trials.
†n=500 trials; excludes crossover and split body trials.
“Randomised” in title
Primary outcome
Sample size calculation
Sequence generation
Allocation concealment
Blinding
Participant flow diagram
Loss to follow-up
Funding source
Trial registration
1.53 (1.22 to 1.92)
1.48 (1.28 to 1.72)
1.63 (1.37 to 1.94)
1.59 (1.27 to 1.98)
1.75 (1.33 to 2.30)
1.53 (1.17 to 1.99)
2.05 (1.58 to 2.68)
1.30 (1.17 to 1.44)
1.22 (1.08 to 1.38)
5.33 (2.82 to 10.08)
113/274
176/274
158/274
117/274
91/274
88/274
107/274
215/274
188/274
47/274
12 0.5 5 0.2
Risk ratio (95% CI) Risk ratio (95% CI) Subgroup Endorsing
92/342
148/342
121/342
92/342
65/342
72/342
65/342
207/342
192/342
11/342
Non-endorsing
Events/Total
Favours
non-endorsing
Favours
endorsing
Fig 3 | Differences in reporting of methodological items between CONSORT endorsing and non-
endorsing journals in 2006
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between2000and2006.The2000sampleincluded all
reports of randomised trials published in December
2000andindexedinPubMedbyJuly2002(toaccount
for the time lag in PubMed indexing). For pragmatic
reasons, the 2006 sample included trials published in
PubMed in December 2006 and indexed as of March
2007. This approach meant that we were able to cap-
tureoursampleoftrialswithinonesearch,butwe may
have missed a small number of eligible trials that were
indexed in PubMed after March 2007.
Finally, it is important to recognise that poor report-
ing does not necessarily mean poor methods. Several
studies
2425 that compared the content of published
reports with their protocol found that the methodolo-
gicaltechniquesintheactualtrialwereofbetterquality
than reported in the final publication. Conversely,
other studies
2627 have shown that important informa-
tionaboutthetrialmethodologyisoftenmissinginthe
protocol but is included in the published report. Such
studies recommend reviewing research protocols and
contacting trialists for more information when asses-
sing trial quality; we did not do this in our study.
Conclusions
Without complete and transparent reporting of how a
trialwasdesignedandconducted,itisdifficultforread-
ers to assess its conduct and validity or to differentiate
trials with unbiased results from those with question-
able results.
22 We believe that the CONSO
RT Statement, and its extensions,is a key tool through
which adequatereportingcan be achieved. Morejour-
nals should endorse the CONSORT Statement, and,
most importantly, they should do more to ensure
adherence. For example, journals could incorporate
the checklist and flow diagram into their review pro-
cesses and indicate this requirement in their published
instructions to authors.
28 Without wide endorsement,
the CONSORT Statement cannot fully yield the ben-
efits it was intended to produce.
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